Standard

PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells. / Fedorova, Iana ; Vasileva, Aleksandra ; Selkova, Polina ; Абрамова, Марина Викторовна; Arseniev, Anatolii; Pobegalov, Georgii ; Kazalov, Maksim ; Musharova, Olga ; Goryanin, Ignatiy ; Artamonova, Daria ; Zyubko, Tatyana ; Shmakov, Sergey ; Artamonova, Tatyana O.; Khodorkovskii, Mikhail; Severinov, Severinov.

In: Nucleic Acids Research, Vol. 48, No. 21, 05.11.2020, p. 12297-12309.

Research output: Contribution to journal › Article › peer-review

Harvard

Fedorova, I, Vasileva, A, Selkova, P, Абрамова, МВ, Arseniev, A, Pobegalov, G, Kazalov, M, Musharova, O, Goryanin, I, Artamonova, D, Zyubko, T, Shmakov, S, Artamonova, TO, Khodorkovskii, M & Severinov, S 2020, 'PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells', Nucleic Acids Research, vol. 48, no. 21, pp. 12297-12309. https://doi.org/10.1093/nar/gkaa998

APA

Fedorova, I., Vasileva, A., Selkova, P., Абрамова, М. В., Arseniev, A., Pobegalov, G., Kazalov, M., Musharova, O., Goryanin, I., Artamonova, D., Zyubko, T., Shmakov, S., Artamonova, T. O., Khodorkovskii, M., & Severinov, S. (2020). PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells. Nucleic Acids Research, 48(21), 12297-12309. https://doi.org/10.1093/nar/gkaa998

Vancouver

Fedorova I, Vasileva A, Selkova P, Абрамова МВ, Arseniev A, Pobegalov G et al. PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells. Nucleic Acids Research. 2020 Nov 5;48(21):12297-12309. https://doi.org/10.1093/nar/gkaa998

Author

Fedorova, Iana ; Vasileva, Aleksandra ; Selkova, Polina ; Абрамова, Марина Викторовна ; Arseniev, Anatolii ; Pobegalov, Georgii ; Kazalov, Maksim ; Musharova, Olga ; Goryanin, Ignatiy ; Artamonova, Daria ; Zyubko, Tatyana ; Shmakov, Sergey ; Artamonova, Tatyana O. ; Khodorkovskii, Mikhail ; Severinov, Severinov. / PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells. In: Nucleic Acids Research. 2020 ; Vol. 48, No. 21. pp. 12297-12309.

BibTeX

@article{4dc883a076a94b8fab97c701b21be11b,
title = "PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells",
abstract = "CRISPR-Cas defense systems opened up the field of genome editing due to the ease with which effector Cas nucleases can be programmed with guide RNAs to access desirable genomic sites. Type II-A SpCas9 from Streptococcus pyogenes was the first Cas9 nuclease used for genome editing and it remains the most popular enzyme of its class. Nevertheless, SpCas9 has some drawbacks including a relatively large size and restriction to targets flanked by an {\textquoteleft}NGG{\textquoteright} PAM sequence. The more compact Type II-C Cas9 orthologs can help to overcome the size limitation of SpCas9. Yet, only a few Type II-C nucleases were fully characterized to date. Here, we characterized two Cas9 II-C orthologs, DfCas9 from Defluviimonas sp.20V17 and PpCas9 from Pasteurella pneumotropica. Both DfCas9 and PpCas9 cleave DNA in vitro and have novel PAM requirements. Unlike DfCas9, the PpCas9 nuclease is active in human cells. This small nuclease requires an {\textquoteleft}NNNNRTT{\textquoteright} PAM orthogonal to that of SpCas9 and thus potentially can broaden the range of Cas9 applications in biomedicine and biotechnology.",
author = "Iana Fedorova and Aleksandra Vasileva and Polina Selkova and Абрамова, {Марина Викторовна} and Anatolii Arseniev and Georgii Pobegalov and Maksim Kazalov and Olga Musharova and Ignatiy Goryanin and Daria Artamonova and Tatyana Zyubko and Sergey Shmakov and Artamonova, {Tatyana O.} and Mikhail Khodorkovskii and Severinov Severinov",
year = "2020",
month = nov,
day = "5",
doi = "10.1093/nar/gkaa998",
language = "English",
volume = "48",
pages = "12297--12309",
journal = "Nucleic Acids Research",
issn = "0305-1048",
publisher = "Oxford University Press",
number = "21",

}

RIS

TY - JOUR

T1 - PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells

AU - Fedorova, Iana

AU - Vasileva, Aleksandra

AU - Selkova, Polina

AU - Абрамова, Марина Викторовна

AU - Arseniev, Anatolii

AU - Pobegalov, Georgii

AU - Kazalov, Maksim

AU - Musharova, Olga

AU - Goryanin, Ignatiy

AU - Artamonova, Daria

AU - Zyubko, Tatyana

AU - Shmakov, Sergey

AU - Artamonova, Tatyana O.

AU - Khodorkovskii, Mikhail

AU - Severinov, Severinov

PY - 2020/11/5

Y1 - 2020/11/5

N2 - CRISPR-Cas defense systems opened up the field of genome editing due to the ease with which effector Cas nucleases can be programmed with guide RNAs to access desirable genomic sites. Type II-A SpCas9 from Streptococcus pyogenes was the first Cas9 nuclease used for genome editing and it remains the most popular enzyme of its class. Nevertheless, SpCas9 has some drawbacks including a relatively large size and restriction to targets flanked by an ‘NGG’ PAM sequence. The more compact Type II-C Cas9 orthologs can help to overcome the size limitation of SpCas9. Yet, only a few Type II-C nucleases were fully characterized to date. Here, we characterized two Cas9 II-C orthologs, DfCas9 from Defluviimonas sp.20V17 and PpCas9 from Pasteurella pneumotropica. Both DfCas9 and PpCas9 cleave DNA in vitro and have novel PAM requirements. Unlike DfCas9, the PpCas9 nuclease is active in human cells. This small nuclease requires an ‘NNNNRTT’ PAM orthogonal to that of SpCas9 and thus potentially can broaden the range of Cas9 applications in biomedicine and biotechnology.

AB - CRISPR-Cas defense systems opened up the field of genome editing due to the ease with which effector Cas nucleases can be programmed with guide RNAs to access desirable genomic sites. Type II-A SpCas9 from Streptococcus pyogenes was the first Cas9 nuclease used for genome editing and it remains the most popular enzyme of its class. Nevertheless, SpCas9 has some drawbacks including a relatively large size and restriction to targets flanked by an ‘NGG’ PAM sequence. The more compact Type II-C Cas9 orthologs can help to overcome the size limitation of SpCas9. Yet, only a few Type II-C nucleases were fully characterized to date. Here, we characterized two Cas9 II-C orthologs, DfCas9 from Defluviimonas sp.20V17 and PpCas9 from Pasteurella pneumotropica. Both DfCas9 and PpCas9 cleave DNA in vitro and have novel PAM requirements. Unlike DfCas9, the PpCas9 nuclease is active in human cells. This small nuclease requires an ‘NNNNRTT’ PAM orthogonal to that of SpCas9 and thus potentially can broaden the range of Cas9 applications in biomedicine and biotechnology.

UR - https://www.mendeley.com/catalogue/77d8d174-1e3a-333f-9dc2-207563fea439/

U2 - 10.1093/nar/gkaa998

DO - 10.1093/nar/gkaa998

M3 - Article

C2 - 33152077

VL - 48

SP - 12297

EP - 12309

JO - Nucleic Acids Research

JF - Nucleic Acids Research

SN - 0305-1048

IS - 21

ER -

ID: 71334127